Clinical Trial Update: Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients [Phase 1]

View source ↗

Summary

This clinical trial update indicates that THEO-260 is being studied via intraperitoneal administration in ovarian cancer and is currently recruiting for a Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• THEO-260

Snippet

Sponsor: Theolytics Limited | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING